KRAS and colorectal carcinoma: Although this is a novel approach to treat KRAS G12C–mutated advanced CRC, only this small subset of KRAS-mutated patients will benefit, as most other patients with KRAS-mutated types remain untargeted, and further work is required to understand the biology of KRAS-mutated CRC, to directly target other KRAS mutations with new selective agents and combinations, and metabolic pathway inhibitors, to indirectly target MAPK signaling (Klempner et al., 2022; Kuboki et al., 2022).